Search

Ardelyx Inc

Suletud

SektorTervishoid

3.77 1.62

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.67

Max

3.77

Põhinäitajad

By Trading Economics

Sissetulek

21M

-17M

Müük

26M

121M

Aktsiakasum

-0.07

Kasumimarginaal

-13.833

Töötajad

489

EBITDA

20M

-10M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+267.39% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

29. okt 2026

Turustatistika

By TradingEconomics

Turukapital

-254M

976M

Eelmine avamishind

2.15

Eelmine sulgemishind

3.77

Uudiste sentiment

By Acuity

67%

33%

298 / 339 Pingereas Healthcare

Ardelyx Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. sept 2026, 20:08 UTC

Ardelyx Inc is rising on biotechnology sector strength during Wednesday's session, despite being below its 20-day moving average and near the one-month range low.

1. sept 2026, 23:06 UTC

Ardelyx Inc shares are lower in after-market hours, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

31. aug 2026, 20:07 UTC

Ardelyx Inc shares are lower amid broader market pressure from comments at the Jackson Hole Economic Symposium about persistent inflation and potential rate hikes.

28. aug 2026, 20:08 UTC

Ardelyx Inc. shares are trading roughly flat amid no specific news. The stock remains near the lower end of its one-month trading range.

26. aug 2026, 19:16 UTC

Ardelyx Inc. shares are higher Wednesday, recovering from an earlier dip amid notable volatility and broader market dynamics reflecting persistent inflationary pressures.

25. aug 2026, 20:07 UTC

Ardelyx Inc shares are gaining amid broader market trends, supported by easing Treasury yields. The stock remains below its 20-day moving average.

21. aug 2026, 19:16 UTC

Ardelyx Inc shares are higher today, continuing positive momentum since Thursday. No specific news was identified to explain the price movement.

20. aug 2026, 20:01 UTC

News

Ardelyx Inc shares are lower amid a securities investigation into its revised IBSRELA revenue guidance, which was cut to $350-$370 million.

19. aug 2026, 23:01 UTC

Ardelyx Inc. shares are higher in after-market trading, reflecting broader market gains. The stock remains below its 20-day moving average.

18. aug 2026, 23:06 UTC

Ardelyx Inc. shares are roughly flat in after-market trading. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

17. aug 2026, 19:26 UTC

News

Ardelyx shares are lower as Levi & Korsinsky investigates potential federal securities law violations amid reduced revenue guidance for IBSRELA.

14. aug 2026, 23:56 UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

13. aug 2026, 23:01 UTC

Ardelyx Inc. shares advanced modestly in after-market trading, though they remain significantly below the 20-day moving average and near the one-month range's lower end.

12. aug 2026, 23:26 UTC

Ardelyx Inc. shares were trading roughly flat in after-market hours. The stock has declined significantly over the past month amid broader market weakness.

11. aug 2026, 19:56 UTC

Ardelyx Inc's shares are lower today, reflecting a broader decline in the biotechnology sector. Investors monitor macroeconomic factors ahead of the Consumer Price Index report.

10. aug 2026, 23:56 UTC

Ardelyx Inc shares are higher in after-market trading, despite no specific news driving the move. Recent market conditions include cautious optimism following a jobs report.

7. aug 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

6. aug 2026, 23:31 UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

3. aug 2026, 19:16 UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

31. juuli 2026, 19:16 UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

30. juuli 2026, 23:51 UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

22. juuli 2026, 19:31 UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

20. juuli 2026, 19:02 UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Võrdlus sarnastega

Hinnamuutus

Ardelyx Inc Prognoos

Hinnasiht

By TipRanks

267.39% tõus

12 kuu keskmine prognoos

Keskmine 13.63 USD  267.39%

Kõrge 18 USD

Madal 9 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ardelyx Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

8

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

298 / 339 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
help-icon Live chat